Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 28,733 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 28,733 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $275.00, for a total value of $7,901,575.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at $8,688,900. This represents a 47.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Performance

Shares of CRL traded up $4.70 during mid-day trading on Tuesday, hitting $281.70. The stock had a trading volume of 1,180,097 shares, compared to its average volume of 926,631. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $282.39. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The business has a fifty day moving average price of $216.74 and a 200-day moving average price of $189.45. The firm has a market cap of $13.45 billion, a P/E ratio of -58.08, a PEG ratio of 2.77 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the company earned $3.12 EPS. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analyst outlook remains broadly favorable. Piper Sandler set a $300 price target, while Barclays maintained an “overweight” rating with the same target and RBC raised its objective to $282 while rating CRL “outperform.” Overall, 12 analysts rate the stock a Buy, three rate it Hold and one rates it Sell, producing a consensus “Moderate Buy” rating. Charles River Laboratories International Sets New 52-Week High
• Positive Sentiment: Recent quarterly results exceeded expectations. Charles River reported adjusted earnings of $3.02 per share versus the $2.77 consensus estimate, while revenue of approximately $1 billion topped expectations of $980.5 million. Fiscal 2026 earnings guidance remains $11.15–$11.45 per share, reinforcing the investment case despite uneven year-over-year results.
• Neutral Sentiment: International markets are a key focus for investors. A recent analysis examined changes in Charles River’s international revenue and how those trends could affect Wall Street forecasts and the stock’s future performance. International Markets and Charles River: A Deep Dive for Investors
• Negative Sentiment: Executive stock sales may weigh on sentiment. EVP Victoria Creamer sold 4,179 shares for approximately $1.08 million, reducing her position by 12.21%. Chief Accounting Officer Michael Gunnar Knell separately sold 6,645 shares worth about $1.73 million, cutting his holdings by 35.92%. These transactions are not necessarily negative fundamental signals, but they can raise caution after the stock’s strong rally.
• Negative Sentiment: Some fundamental risks remain. Quarterly revenue declined 2.7% year over year, earnings fell from $3.12 per share in the prior-year period, and the company reported a negative net margin. The consensus price target of $255.65 is also below recent trading levels, suggesting analysts may see limited near-term upside despite the positive ratings.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. boosted its position in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after acquiring an additional 1,446,972 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $176,478,000. Victory Capital Management Inc. increased its holdings in Charles River Laboratories International by 9,938.8% during the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares during the period. Ameriprise Financial Inc. lifted its stake in Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after purchasing an additional 575,039 shares in the last quarter. Finally, Amundi lifted its stake in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after purchasing an additional 492,301 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. Royal Bank Of Canada boosted their price target on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Mizuho set a $264.00 price objective on shares of Charles River Laboratories International in a report on Monday. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $180.00 to $310.00 in a research note on Thursday, August 6th. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a report on Monday, July 20th. Finally, Robert W. Baird set a $291.00 target price on Charles River Laboratories International in a research report on Thursday, August 6th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.